GlassScriptPhysician profile
Shawn K Brunk
NPI 1558303404
$3,142.46
in general payments reported to CMS, 2019-2025
27 companies · $34.64 in 2025
The $34.64 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,004 · 2020: $415 · 2021: $201 · 2022: $131 · 2023: $71.14 · 2024: $285 · 2025: $34.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $510.20 | 2019-2022 | |
| Novo Nordisk INC | $483.98 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $397.22 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $258.16 | 2021-2024 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $216.84 | 2019-2025 | |
| Glaxosmithkline, LLC. | $186.10 | 2019-2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $150.44 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.50 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.35 | 2019 | |
| Neos Therapeutics, LP | $89.10 | 2019-2020 | |
| Astellas Pharma US INC | $83.15 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.26 | 2019-2020 | |
| Shire North American Group INC | $78.69 | 2019 | |
| Lilly USA, LLC | $76.52 | 2019 | |
| Amgen INC. | $48.50 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $38.24 | 2019-2024 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $36.40 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $28.56 | 2019 | |
| Amarin Pharma, INC. | $17.61 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.99 | 2019 | |
| Exact Sciences Corporation | $15.96 | 2024 | Cologuard Collection Kit |
| Bausch Health US, LLC | $15.70 | 2019 | |
| Gilead Sciences, INC. | $14.12 | 2019 | |
| Seqirus USA INC | $13.61 | 2019 | |
| Allergan, INC. | $13.02 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $12.26 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Brunk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.